20th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160136164 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders - The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B—C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently. | 2016-05-19 |
20160136165 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders - The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence. | 2016-05-19 |
20160136166 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS - Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described. | 2016-05-19 |
20160136167 | USE OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE IN TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES - Provided herein are methods of using compounds and compositions for modulating lymphocytic activity, including activity of B cells and/or T cells, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein. | 2016-05-19 |
20160136168 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER - The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent. | 2016-05-19 |
20160136169 | SYSTEMS AND METHODS FOR DELIVERY OF TETRAHYDROBIOPTERIN AND RELATED COMPOUNDS - The present invention generally relates to compositions and methods for the delivery of tetrahydrobiopterin and/or related compounds through the skin. In general, tetrahydrobiopterin may react with oxygen, and various formulations discussed herein may prevent or reduce the ability of tetrahydrobiopterin to react with oxygen. For example, in some aspects, the tetrahydrobiopterin may be contained with a composition comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, liquid crystals, or other configurations. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-05-19 |
20160136170 | USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY - The present invention relates to methods of delaying progression to end stage renal disease (ESRD) in patients comprising administration of 1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methylpyridin-2-yl)amino)-N-(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide. The present invention also includes administration of pharmaceutical compositions for delaying progression to ESRD. | 2016-05-19 |
20160136171 | Combination Therapy Comprising A CDK4/6 Inhibitor and a PI3K Inhibitor for Use in the Treatment of Cancer - A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer. | 2016-05-19 |
20160136172 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 2016-05-19 |
20160136173 | Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - III - The present invention relates to a method for the prevention and/or treatment of chronic traumatic encephalopathy comprising administration of an effective amount of aprepitant (otherwise known as emend, fosaprepitant, ivemend, L754030, and ONO-7436). The invention further relates to the inhibition of progression of a disease, condition or state associated with tau hyperphosphorylation, and the treatment of a subject with a concussive injury. | 2016-05-19 |
20160136174 | SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDIN- E-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed. | 2016-05-19 |
20160136175 | COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (I) and (b) a mTOR inhibitor for the treatment of a target of rapamycin (mTOR) kinase dependent disease, especially a cancer disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 2016-05-19 |
20160136176 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 2016-05-19 |
20160136177 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN - There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin. | 2016-05-19 |
20160136178 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME - Provided are immediate or prolonged administration of certain potassium ATP (K | 2016-05-19 |
20160136179 | Compositions For Treating Acute, Post-Operative, Or Chronic Pain and Methods of Using the Same - Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. Methods of treating pain in a subject and kits for producing compositions for treating acute, chronic or post-operative pain in in a subject are also disclosed herein. | 2016-05-19 |
20160136180 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES - The invention is directed to the use of selected purine derivatives for the treatment of hyperproliferative diseases. | 2016-05-19 |
20160136181 | MICRORNA DOSING REGIMENS - A method of treating a subject, for example for a subject with a solid tumor or hematologic malignancy, can include administering a therapeutic treatment cycle to the subject, the cycle including daily microRNA mimic administrations on the first 3-7 consecutive days of the cycle followed by no microRNA administration on the next 7-21 consecutive days of the cycle. | 2016-05-19 |
20160136182 | METHODS FOR DIAGNOSING AND TREATING ASTHMA - The present invention relates to asthma. Particularly, the present invention relates to clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development for the treatment of asthma. The present invention relates to a new paradigm in diagnosing, screening, and treating asthma by affecting airway epithelial synchronization. | 2016-05-19 |
20160136183 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING - The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof. | 2016-05-19 |
20160136184 | Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism - Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D | 2016-05-19 |
20160136185 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECT OF STEROID IN SUBJECT COMPRISING ACETYLSALICYLIC ACID AND USE THEREOF - A method for preventing or treating side effects of glucocorticoid in a subject including administrating to a subject acetylsalicylic acid a pharmaceutically acceptable salt, solvate, or polymorph thereof, or a combination of at least two of the foregoing. | 2016-05-19 |
20160136186 | DIRECT MEDICAMENT PERIODONTAL DELIVERY METHOD AND ASSEMBLY FOR REDUCTION OF THE SYSTEMIC INFLAMMATORY MARKERS - Methods and systems for reducing an identified systemic inflammatory marker associated with cardiovascular disease in a patient is provided through periodontal treatment that includes identifying an oral periopathogen related to the systemic inflammatory marker and a biofilm and an environment associated with the periopathogen, preparing a periodontal tray for direct application of a selected medicament having a efficacy in regard to the identified oral periopathogen and biofilm of the gum tissue associated with the one application region in which the medicament is to be placed and applying the tray with the placed selected medicament to the treatment region of the patient such that at least a portion of the selected medicament is forced into a gingival sulcus or periodontal pocket of the gum tissue of the treatment region and monitoring and continuing treatment to reduce the identified systemic inflammatory marker. | 2016-05-19 |
20160136187 | MODIFIED RELEASE DOXYCYCLINE COMPOSITION - Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed. | 2016-05-19 |
20160136188 | METHODS OF TREATING ACNE - A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound. | 2016-05-19 |
20160136189 | METHODS FOR TREATING AND PREVENTING PROSTATE CANCER BONE METASTASES - Methods for treating a subject having a prostate cancer bone metastasis are disclosed. Methods for prophylactically treating a subject at risk of developing a prostate cancer bone metastasis are also disclosed. The methods for treating a subject having, or at risk of developing, a prostate cancer bone metastasis may include administering a prostatic acid phosphatase inhibiting agent to the subject. The methods for treating a subject having, or at risk of developing, a prostate cancer bone metastasis may also include administering a phosphonic acid to the subject. Further, the phosphonic acid may include a benzylaminophosphonic acid, such as [phenyl[(phenylmethyl)amino]methyl]-phosphonic acid). | 2016-05-19 |
20160136190 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles - The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds. | 2016-05-19 |
20160136191 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses - The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. | 2016-05-19 |
20160136192 | METHODS AND COMPOSITIONS FOR ENHANCING COGNITIVE PERFORMANCE - Compositions including an effective amount of each of phosphatidyl serine, choline, and oleic acid, and methods for improving cognitive performance that include administering such compositions to a subject, are described herein. The compositions can be nutritional compositions such as bars or liquids suitable for oral administration. The combination of phosphatidyl serine, choline, and oleic acid provides synergistic or complimentary modes of action that improve the overall effect of these compounds. | 2016-05-19 |
20160136193 | TREATMENT OF SYMPTOMS ASSOCIATED WITH BACTERIAL VAGINOSIS - The invention relates to the use of saccharide, such as lactose for the preparation of a medicament for the treatment and/or prophylaxis of one or more symptoms caused by bacterial vaginosis, wherein the medicament comprises at least 20 percent by weight of saccharide, and wherein the medicament is substantially free from bacteria. Furthermore, the invention relates to a method for treating one or more symptoms associated with bacterial vaginosis, as well as a pharmaceutical composition comprising the saccharide. | 2016-05-19 |
20160136194 | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum - A pharmaceutical composition including proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of H. pylori from the gastric and duodenal mucosa to be carried out without using wide-spectrum antibiotics. The comprehensive treatment of ulcer disease associated with a helicobaterial infection using a pharmaceutical composition of a PPI and a prebiotic makes it possible, in conditions of an elevated pH of the stomach contents, actively to stimulate the growth of lactobacilli in the upper sections of the gastrointestinal tract, including the duodenum, and substantially to increase the titre of lactobacilli, which are antagonists of H. pylori, which greatly improves the effectiveness of the ulcer treatment. | 2016-05-19 |
20160136195 | USE OF HGMA-TARGETED PHOSPHOROTHIOATE DNA APTAMERS TO SUPPRESS CARCINOGENIC ACTIVITY AND INCREASE SENSITIVITY TO CHEMOTHERAPY AGENTS IN HUMAN CANCER CELLS - Elevated high mobility group A (HMGA) protein expression in human cancer cells, and especially human pancreatic cancer cells, is correlated with resistance to the chemotherapy agent gemcitabine. The present invention uses HMGA-targeted AT-rich phosphorothioate DNA (AT-sDNA) aptamers to suppress HMGA carcinogenic activity. Cell growth of human pancreatic cancer cells (AsPC-1 and Miapaca-2) transfected with AT-sDNA were monitored after treatment with gemcitabine. Significant increases in cell death in AT-sDNA transfected cells compared to non AT-rich sDNA treated cells were observed in both cell lines. The data indicates the potential use of HMGA targeted DNA aptamers to enhance chemotherapy efficacy in human cancer treatment, and in particular human pancreatic cancer treatment. | 2016-05-19 |
20160136196 | Methods for Treating Pulmonary Hypertension - The present invention relates to methods for treating or preventing pulmonary hypertension, reducing mortality in a subject experiencing pulmonary hypertension, or inhibiting ADP-mediated vasoconstriction of pulmonary arteries in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a reversible P2Y | 2016-05-19 |
20160136197 | Pharmaceutical Compositions Comprising a GPG Oligodeoxynucleotide and Cyclic Di-GMP - The present invention relates to pharmaceutical compositions comprising an immunostimulatory amount of at least two immunopotentiators, wherein a first immunopotentiator is a non-methylated cytidyl guanosyl oligodeoxynucleotide (CpG ODN) and a second immunopotentiator is 3′,5′-cyclic diguanylic acid (c-di-GMP), and a pharmaceutically acceptable carrier. The invention also relates to the use of such pharmaceutical compositions for the induction of an immune response against tumor-specific antigens. Also the invention relates to their use in in situ tumor-destruction therapy and to such pharmaceutical compositions for use in the treatment of a mammal suffering from cancer. | 2016-05-19 |
20160136198 | Use of Immobilization Particles for Removal of Microorganisms and/or Chemicals - Method for immobilizing a target microorganism or target chemical found in a mammal includes introducing into a gastrointestinal tract of the mammal immobilization particles including immobilization molecules capable of attaching to the target microorganism or the target chemical, which immobilization molecules are attached to one or more portions of a structure that is capable of inhibiting contact between tissues of the gastrointestinal tract and the target microorganisms or target chemicals attached to the immobilization molecules. | 2016-05-19 |
20160136199 | POLYPEPTIDE HAVING THE ABILITY TO FORM CONNECTIONS OF GLUCOSYL UNITS IN ALPHA-1,3 ON AN ACCEPTOR - An isolated polypeptide having the ability to specifically form connections of glucosyl units in alpha 1,3 on an acceptor including at least one hydroxyl moiety. The polypeptide includes i) the pattern I of sequence SEQ ID NO: 1, ii) the pattern II of sequence SEQ ID NO: 2, iii) the pattern II of sequence SEQ ID NO: 3, iv) the pattern IV of sequence SEQ ID NO: 4 or derivates from one or several of said patterns. The polypeptide furthermore has the aspartic residue (D) in position 5 of the pattern II (SEQ ID NO: 2), the glutamic acid residue (E) at position 6 of the pattern III (SEQ ID NO: 3) and the aspartic acid residue (D) in position 6 of the pattern IV (SEQ ID NO: 4); and its uses. | 2016-05-19 |
20160136200 | GASTROINTESTINAL HEALTH, IMMUNITY AND PERFORMANCE BY DIETARY INTERVENTION - This invention relates to the improvement of gastrointestinal health, immunity and performance by direct dietary intervention with a composition comprising a glucan and/or a fucan, and relates in particular to the transfer of associated health benefits to offspring via glucan and/or a fucan supplementation of the maternal diet. Accordingly the present invention provides a composition comprising at least one glucan, at least one fucan, or at least one glucan and at least one fucan for use in improving or maintaining the gastrointestinal health or function of a progeny of a maternal animal by administration to the maternal animal; and a method for improving or maintaining the gastrointestinal health or function of a progeny of a maternal animal, the method comprising administering a composition comprising at least one glucan, at least one fucan, or at least one glucan and at least one fucan to the maternal animal. | 2016-05-19 |
20160136201 | METHOD OF MEDICALLY TREATING EBOLA AND OTHER ORGANISMS - A method of treating Ebola in a human patient includes covering sensitive body parts of the patent, and immersing the patient in a bath of sodium hypochlorite solution. A concentration of the sodium hypochlorite in the solution being high enough that the solution penetrates skin of the patient to react with fat tissue of the skin. | 2016-05-19 |
20160136202 | ANTI-VIRAL WASH - An anti-viral wash composition composed of approximately 0.005% to 1.0% (wt.) aluminum hydroxide, approximately 0.1% to 0.001% (wt) sodium bicarbonate and approximately 0.1% to 0.001% (wt) trisodium phosphate. | 2016-05-19 |
20160136203 | SOMATIC STEM CELLS FOR TREATING BONE DEFECTS - A method of treating a bone defect in a subject, comprising administering to a subject in need thereof at a bone defect site an effective amount of isolated somatic stem cells, wherein the somatic stem cells are about 2 to 8.0 μm in size and are Lgr5+ or CD349+. | 2016-05-19 |
20160136204 | PRODUCTION AND THERAPEUTIC USES OF TH1-LIKE REGULATORY T CELLS - A unique CD4 | 2016-05-19 |
20160136205 | TARGETING TYPE I NKT CELLS TO CONTROL INFLAMMATION - Embodiments are directed to methods and compositions for modulating cytokine responses in subject infected by a pathogen. | 2016-05-19 |
20160136206 | COMPOSITIONS AND METHODS FOR TREATING SKIN - The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment of skin | 2016-05-19 |
20160136207 | CD34 STEM CELL-RELATED METHODS AND COMPOSITIONS - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated. | 2016-05-19 |
20160136208 | APPLICATION OF ADSORBED DRONE BROOD HOMOGENATE AND OF VITAMIN D3 OR D-GROUP VITAMINS AND/OR ACTIVE METABOLITES THEREOF FOR PREVENTING AND TREATING VIRAL DISEASES - The invention relates to medicine, in particular, to agents for prophylaxis and treatment of conditions associated with various forms of catarrhal diseases, as well as for immunity improvement. | 2016-05-19 |
20160136209 | STRAIN FOR THE TREATMENT AND/OR PREVENTION OF CHRONIC INFLAMMATORY DISEASES - The present invention concerns the probiotic strain | 2016-05-19 |
20160136210 | SYNBIOTIC COMPOSITION FOR TREATMENT OF INFECTIONS IN ALLERGIC PATIENTS - The invention concerns the use of prebiotics and probitics for the treatment of infections in allergic patients. | 2016-05-19 |
20160136211 | METHODS FOR THE TREATMENT OF BLADDER CANCER - The present invention relates to methods of treating bladder cancer with human enterovirus C (HEC) in combination with chemotherapy or radiation therapy. The present invention also relates to methods for increasing susceptibility of a cancer cell to infection by HEC. | 2016-05-19 |
20160136212 | MYXOMA VIRUS MUTANTS FOR CANCER TREATMENT - Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer. | 2016-05-19 |
20160136213 | Process to suspend cannabis oil in glycerin - The applied for method of inserting cannabis oil into glycerin represents a significant improvement over the current technology today. First, no reliable or food safe suspension mechanism exists in the medical marijuana market today. The applied for technology could be used immediately to administer the medication and also to control concentration of the medication. There are current technologies that are in use in the hemp oil and recreational markets, but none are as food safe as the applied for method. | 2016-05-19 |
20160136214 | SESAME SEED OIL AQUEOUS EXTRACTS AND METHODS OF MAKING AND USING THEREOF - Described are compositions and methods for extracting non-lipid, aqueous components from sesame seed oil. Such compositions are useful for methods of preventing, treating and inhibiting the effects of inflammation in the body. The methods disclosed involve the use of sesame seed oil aqueous extracts for the treatment and prevention of inflammatory related conditions including atherosclerosis, arthritis, diabetes, mental conditions and vision impairment. | 2016-05-19 |
20160136215 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN - The present invention relates to a homeopathic formulation comprising dilutions of | 2016-05-19 |
20160136216 | Molecular and Herbal Combinations for Treating Psoriasis - A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including emodin and digoxin, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang, Jin Yin Hua, Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi. | 2016-05-19 |
20160136217 | COMPOSITION CONTAINING COMPOSITE EXTRACT OF REHMANNIA GLUTINOSA AND PUERARIA LOBATA FOR PREVENTING OR TREATING MENOPAUSAL SYMPTOMS - The present invention relates to a composition and functional health food containing a composite extract of | 2016-05-19 |
20160136218 | Molecular and Herbal Combinations for Disease Therapy - A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination including emodin or digoxin, or both, with Sheng Di Huang or Da Huang, or both, and/or Jin Yin Hua. | 2016-05-19 |
20160136219 | Molecular and Herbal Combinations for Treating Psoriasis - A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including emodin and digoxin, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang, Jin Yin Hua, Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi. | 2016-05-19 |
20160136220 | Molecular and Herbal Combinations for Treating Psoriasis - A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including emodin and digoxin, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang, Jin Yin Hua, Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi. | 2016-05-19 |
20160136221 | Molecular and Herbal Combinations for Treating Psoriasis - A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of the above with Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi. | 2016-05-19 |
20160136222 | Molecular and Herbal Combinations for Treating Psoriasis - A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of the above with Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi. | 2016-05-19 |
20160136223 | Molecular and Herbal Combinations for Treating Psoriasis - A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including emodin and digoxin, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of emodin, digoxin, Sheng Di Huang, Da Huang, Jin Yin Hua, Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi. | 2016-05-19 |
20160136224 | METHOD FOR PREPARING A CAMELLIA NITIDISSIMA CHI LIPID-LOWERING AND HYPOGLYCEMIC AGENT - The present invention discloses a method for preparing a | 2016-05-19 |
20160136225 | METHODS AND COMPOSITIONS FOR ENHANCING STEM CELL MOBILIZATION - The present invention provides a method of using mobilization agents to enhance stem cell mobilization in a subject, including hematopoietic stem cells (HSCs) and bone marrow stem cells (BMSCs). In one embodiment, a blended composition of fruits, mushrooms, microorganisms, maternal fluids, and extracts thereof are used to promote trafficking of stem cells, resulting in migration of the stem cells to specific sites of maintenance and repair within tissues and/or organs. Increased circulation of HSCs and/or BMSCs and migration towards sites of maintenance and the natural regeneration mechanisms in the body. Further provided is a dosing regimen for the administration of fucoidan and a method of enhancing release and circulation of stem cells. | 2016-05-19 |
20160136226 | METHOD AND A COMPOSITION HAVING PROPHYLACTIC ACTIVITY AGAINST VENOMS AND TOXINS - A composition to be administered to a patient to prevent harmful effects of biological venom or chemical toxin is described. The composition includes the use of the date palm, | 2016-05-19 |
20160136227 | Pharmaceutical Composition for Anti-Obesity Comprising Complex Extracts, Including Saururi Chinensis Baill. Extract, Curcumae Longae Rhizoma Extract and Polygalae Radix Extract - Disclosed herein are a pharmaceutical composition for the prevention or treatment of obesity comprising an extract of a mixture comprising Saururi chinensis Baill., Curcumae Longae Rhizoma, and Polygalae Radix, or an extract of a mixture comprising Saururi chinensis Baill., Curcumae Longae Rhizoma, Polygalae Radix, and Acori Gramineri Rhizoma; a food composition comprising the extract of the mixture; and a method of manufacturing the extracts of the mixture. The extracts of the present invention can inhibit fat generation without adverse effects such as cellular toxicity and thus can be widely used for the prevention, improvement, or treatment of obesity or obesity-related diseases. | 2016-05-19 |
20160136228 | COMPOSITIONS INCLUDING TRICIRIBINE AND BORTEZOMIB AND DERIVATIVES THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2016-05-19 |
20160136229 | MATERIALS FOR POSITIVE CATHEPSIN B MODULATION AND METHODS OF USE FOR TREATING MILD COGNITIVE IMPAIRMENT (MCI), EARLY DEMENTIA, A-SYNUCLEINOPATHY, TRAUMATIC BRAIN INJURY, CARDIOMYOPATHY, EYE DISEASE AND SKIN DAMAGE - The present invention provides methods for treating a subject afflicted with i) Mild Cognitive Impairment (MCI), ii) early dementia, iii) early α-synucleinopathy, iv) traumatic brain injury, v) cardiomyopathy, vi) eye disease, or vii) skin damage, comprising administering to the subject at least one compound that increases the level of active cathepsin B in cells of the subject, or a pharmaceutically acceptable salt or ester thereof, in an amount that is effective to treat the subject. The present invention also provides compositions for treating a subject afflicted with i) Mild Cognitive Impairment (MCI), ii) early dementia, iii) early α-synucleinopathy, iv) traumatic brain injury, v) cardiomyopathy, vi) eye disease, or vii) skin damage. | 2016-05-19 |
20160136230 | NOVEL COMPOUNDS - A compound of formula (I): | 2016-05-19 |
20160136231 | TOPICAL FORMULATIONS OF CHEMERIN C15 PEPTIDES FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS - Described herein, are topical formulations for treating a dermatological disease, disorder, or condition. Topical formulations disclosed herein include a therapeutically-effective amount of a human chemerin C15 peptide formulated for dermal administration. | 2016-05-19 |
20160136232 | TUNABLE ANTI-MICROBIAL LOADED HYDROGELS - A tunable antimicrobial-loaded hydrogel formulation has a mechanical strength can be altered by changing the salt composition. The hydrogel formulation is preferably a Gellan film. The ion concentration in the gel material may be altered to obtain the desired gel strength. The hydrogel formulation is layered directly upon a skin area such as burnt skin. The hydrogel formulation includes a dosage of free antibiotic, such as the antibiotic is preferably vancomycin, for rapid release. The hydrogel formulation also includes microparticles and/or nanoparticles such as activated carbon powder that has adsorbed additional antibiotic. The particles are used to aid in attaining a timely or sustained release of the antibiotic drug. | 2016-05-19 |
20160136233 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 2016-05-19 |
20160136234 | Compositions and Methods for Preventing or Treating Diseases, Conditions, or Processes Characterized by Aberrant Fibroblast Proliferation and Extracellular Matrix Deposition - The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof. | 2016-05-19 |
20160136235 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 2016-05-19 |
20160136236 | Compositions and Methods of Altering Cholesterol Levels - The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmRNA molecules. The present invention also relates to compositions and methods for altering cholesterol levels using polynucleotides, primary transcripts and mmRNA molecules. | 2016-05-19 |
20160136238 | BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE - Preventing or reducing the symptoms of lactose intolerance in an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. The effect is both acute (post-exposure to the composition) and ongoing (future exposure to lactose). | 2016-05-19 |
20160136239 | METHOD FOR PRODUCING AUTOLOGOUS PROTEINS - A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein. Gold particles are mixed into the blood and the combination of blood and gold particles are allowed to incubate to produce a protein enriched serum. After incubation, the gold particles are removed and the protein enriched serum is administered to a patient such as by syringe injection. | 2016-05-19 |
20160136240 | COMPOSITIONS AND METHODS RELATING TO MYOMAKER-INDUCED MUSCLE CELL FUSION - The present disclosure describes the fusogenic activity of the Myomaker protein. This polypeptide, when expressed in non-muscle cells, is able to drive fusion of the cell with a muscle cell, but not with other non-muscle cells. The use of this protein and cell expressing it in the delivery of exogenous genetic material to muscle cells also is described. | 2016-05-19 |
20160136241 | METHODS OF PREPARING AND USING SERICIN HYDROGEL - A method for preparing a sericin hydrogel, the method including: 1) weighing a cocoon of a fibroin-deficient mutant silkworm, | 2016-05-19 |
20160136242 | Glial Cell Line Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions - The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof. | 2016-05-19 |
20160136243 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2016-05-19 |
20160136244 | METHODS OF USE FOR IL-22 PROMOTING REJUVENATION OF THYMIC AND BONE MARROW FUNCTION - The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination. | 2016-05-19 |
20160136245 | METHODS OF TREATING PAIN USING PROTEIN SOLUTIONS - Methods and compositions for treating pain in mammalian subjects are provided. The methods include obtaining blood or a fraction of blood from the subject, measuring a therapeutic indicator in the blood or in the fraction blood, and administering an anti-inflammatory composition to the subject if the therapeutic indicator is equal to or above a threshold level. The anti-inflammatory composition comprises a protein solution including interleukin-1 receptor antagonist. The protein solution may be prepared from the blood or blood fraction obtained from the subject. | 2016-05-19 |
20160136246 | Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes - The present invention relates to GLP-1 receptor agonists for use in hypoglycaemia or hypoglycaemic episodes in patients treated with insulin and/or suffering from type 1 diabetes, e.g. for reducing the number of hypoglycaemia or hypoglycaemic episodes. | 2016-05-19 |
20160136247 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2016-05-19 |
20160136248 | METHODS AND MATERIALS FOR MODULATING DEUBIQUITINASES AND UBIQUITINATED POLYPEPTIDES - This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided. This document also provides methods and materials for identifying agonists or antagonists of USP10 polypeptide mediated stabilization of p53 polypeptides. | 2016-05-19 |
20160136249 | NOVEL COMPOSITIONS FOR THE TREAMENT OF CANCER - The present invention relates to novel compositions comprising proteolytic enzymes and fining agents as well as methods for the treatment and/or prevention of cancer using these compositions. | 2016-05-19 |
20160136250 | Hydrophobic Preparations - The present invention relates to preparations of substances in hydrophobic solvents in which they would not normally be soluble and to processes for obtaining these preparations. In particular, the invention relates to preparations of hydrophilic species in hydrophobic solvents such as oils. The use of these preparations as vaccines and in pharmaceutical compositions is also described. | 2016-05-19 |
20160136251 | CD4 T Cell Vaccine and Use Thereof - The present invention relates to a CD4 T cell vaccine and a use thereof, and provides a CD4 T cell vaccine which can increase intracellular viability and effectively induce an antigen-specific cytotoxic T lymphocyte (CTL) response. | 2016-05-19 |
20160136252 | IMMUNITY-INDUCING AGENT - An immunity-inducing agent comprising as an effective ingredient(s) a polypeptide(s) selected from the polypeptides: (a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in SEQ ID NOs:2, 4, 6, 8, 10, 12 and 44 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% with the polypeptide (a) and consisting essentially of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof; which polypeptide(s) has/have an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo, is useful as a therapeutic and/or prophylactic agent for cancer, and/or the like. | 2016-05-19 |
20160136253 | VACCINES AGAINST PREGNANCY-ASSOCIATED MALARIA - The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the N-terminal portion of the VAR2CSA protein of different parasitic families or lines of | 2016-05-19 |
20160136254 | METHOD OF MAKING A MYCOPLASMA VACCINE - The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject. | 2016-05-19 |
20160136255 | VACCINATION WITH RECOMBINANT MYCOBACTERIUM TUBERCULOSIS PknD ATTENUATES BACTERIAL DISSEMINATION TO THE BRAIN - Vaccines comprising | 2016-05-19 |
20160136256 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 2016-05-19 |
20160136257 | PROTEIN MATRIX VACCINES AND RELATED METHODS OF MAKING AND ADMINISTERING SUCH VACCINES - The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration. | 2016-05-19 |
20160136258 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2016-05-19 |
20160136259 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2016-05-19 |
20160136260 | ATTENUATED INFLUENZA VACCINES AND USES THEREOF - Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses. | 2016-05-19 |
20160136261 | LIVE ATTENUATED VACCINES FOR INFLUENZA VIRUSES - The subject invention pertains to attenuated influenza viruses, and related vaccines and methods, comprising a genetically modified viral genome. The genetically modified viral genome comprises a disruption in the non-structural (NS1) coding segment and one or more base substitution in the matrix membrane protein coding segment. The genetic modifications result in viruses that lose NS1 functionality, yet remain replication competent. | 2016-05-19 |
20160136262 | INFLUENZA VIRUS VACCINES AND USES THEREOF - Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA | 2016-05-19 |
20160136263 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2016-05-19 |
20160136264 | HEPATITIS B VACCINE - Disclosed is a composition comprising: i) HBsAg, a fragment thereof, a variant thereof, or the mixture of at least two of them, ii) HBcAg1-X, a fragment thereof, a variant of the antigen or the antigen fragment, or the mixture of at least two of them, wherein X is an integer of from 149 to 183, iii) CpG-ODN, 21 bases long, which is a phosphorothioate oligonucleotide and includes two or more copies of 5′-NTCGTT-3′ motifs. The use of the composition in the treatment of HBV-infection and HBV-induced diseases, and the therapy methods of HBV-infection and HBV-induced diseases are also disclosed. | 2016-05-19 |